Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cosmo Bio Company,Limited (3386.T)
Tokyo, JP
Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, specialized kits, scientific instruments, analytical software, and diagnostic products. Among their research reagents, they offer a wide spectrum such as antibodies, antigens, bioactive substances, enzymes, peptides, amino acids, various chemicals, carbohydrates, lipids, and components derived from viruses and bacteria. They also provide crucial detection reagents, cell and tissue culture systems, and gene analysis solutions. In terms of instrumentation, Cosmo Bio supplies electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. Beyond products, the company delivers valuable services like drug discovery support, custom research, and clinical diagnostics. A significant part of their operation involves the development and manufacturing of proprietary cell and cell culture products. This includes a range of specialized cells such as adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, and mesenchymal stem cells, in addition to feeder cells, tumor cell lines, coating reagents, and macrophage-related products. They also produce various assay kits for measurement, staining, detection, and purification. Furthermore, they offer specialized biotechnology research equipment, including constant-temperature transport containers, aluminum block heat insulation devices, and dew condensation prevention glass plates, alongside consigned services for custom peptide synthesis and antibody production. Serving a diverse clientele of laboratories, research institutes, and life science education and testing organizations, Cosmo Bio distributes its products through its own outlets in Japan and an international network of sales agents. The company was founded in Tokyo, Japan, in 1978, where its headquarters remain.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.64% | -1.66% | -2.20% | -7.72% | +12.89% | -4.60% | +6.87% | +31.92% | +1.80% | +4.98% | -38.72% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+7.3% Q1'26: +7.7% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%+31.5% ★ Q1'26: +5.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+1.8% ★ Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+3.2% Q1'26: +8.2% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+3.2% Q1'26: +10.2% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%-2.2% ★ Q1'26: -0.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.04× ★ Q1'26: 0.59× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2017 actual |
|---|---|
| Revenue |
7.07B
est.
|
| EBITDA |
723.45M
est.
|
| EBIT |
605.04M
est.
|
| Net Income |
233.51M
est.
|
| SGA |
2.00B
est.
|
| EPS |
40.15
est.
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-01 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 2/5 | 4/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 2/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Junko Tochigi | MD, Planning Department Manager & Director | — | — |
| Masanori Hayashi | GM of Finance Department & Director | — | — |
| Norihiko Shibayama | President & Chairman | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3386.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
